Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

TRACON Pharmaceuticals, Inc. (TCON)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9300+0.2500 (+14.88%)
At close: 04:00PM EDT
2.0000 +0.07 (+3.63%)
After hours: 06:04PM EDT
Advertisement

TRACON Pharmaceuticals, Inc.

4350 La Jolla Village Drive
Suite 800
San Diego, CA 92122
United States
858 550 0780
https://www.traconpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Dr. Charles P. Theuer M.D., Ph.D.CEO, Pres & Director827.53kN/A1964
Mr. Scott B. Brown CPA, M.S.Chief Financial Officer459.21kN/A1981
Mr. Mark C. Wiggins M.B.A.Chief Bus. Officer506.25kN/A1956
Ms. Bonne AdamsExec. VP of Clinical OperationsN/AN/A1977
Mr. Shahe GarabedianSr. VP & Head of Quality AssuranceN/AN/AN/A
Dr. James L. FreddoChief Medical OfficerN/AN/A1955
Mr. Ya HuangExec. Director of Statistical ProgrammingN/AN/AN/A
Dr. Brenda Marczi Pharm.D., Pharmd MbaSr. VP of Regulatory AffairsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Corporate Governance

TRACON Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement